AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29036630 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs11614164
Number of subjects: 1906
Study 29036630 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs3741914
Number of subjects: 1906
Study 29037247 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Program intervention
Number of subjects: 121
Study 29037247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 121
Study 29037358 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed bandages (elastic and nonelastic)
Number of subjects: 25
Study 29037358 — intervention group
Group type: COMPARATOR
Intervention: Single-component bandages (elastic or nonelastic)
Number of subjects: 25
Study 29037358 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposition of two bandages
Number of subjects: 25
Study 29037358 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed bandages
Number of subjects: 25
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 0.5 mg/kg
Number of subjects: 189
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 1 mg/kg
Number of subjects: 189
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 1.5 mg/kg
Number of subjects: 189
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 3 mg/kg
Number of subjects: 189
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab 6 mg/kg
Number of subjects: 189
Study 29037448 — intervention group
Group type: EXPERIMENTAL
Intervention: bococizumab
Number of subjects: 189
Study 29037448 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 189
Study 29037481 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 1477
Study 29037481 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 1477
Study 29037983 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan at 5.4 mg/kg or greater
Number of subjects: 24
Study 29037983 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 24
Study 29038072 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52 mg IUS
Number of subjects: 1714
Study 29038094 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided version of the transdiagnostic affect-focused psychodynamic Web-based self-help intervention for 10 weeks
Number of subjects: 82
Study 29038094 — intervention group
Group type: COMPARATOR
Intervention: Unguided version of the transdiagnostic affect-focused psychodynamic Web-based self-help intervention after a waiting period of 10 weeks
Number of subjects: 82
Study 29038094 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided version of the intervention for completers
Number of subjects: 82
Study 29038168 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel LDL-C estimation method
Number of subjects: 1545634
Study 29038168 — intervention group
Group type: COMPARATOR
Intervention: Friedewald estimation
Number of subjects: 1545634
Study 29038184 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory action research (PAR) approach to improve antibiotic prescribing quality
Number of subjects: 0
Study 29038184 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSA (Plan-Do-Study-Act) cycles for implementing interventions
Number of subjects: 0
Study 29038184 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation and theory building on improving antibiotic prescribing
Number of subjects: 0
Study 29038277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage (BAL) procedure
Number of subjects: 0
Study 29038338 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy
Number of subjects: 133
Study 29038340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus dacarbazine (DTIC)
Number of subjects: 22
Study 29038340 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV) plus bendamustine
Number of subjects: 22
Study 29038891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 1.5 µg
Number of subjects: 101
Study 29038891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 3 µg
Number of subjects: 101
Study 29038891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 6 µg
Number of subjects: 101
Study 29038891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanocobalamin 9 µg (normal status)
Number of subjects: 101
Study 29038891 — intervention group
Group type: COMPARATOR
Intervention: Cyanocobalamin (6 µg) vs 3 µg (low status)
Number of subjects: 101
Study 29038891 — intervention group
Group type: COMPARATOR
Intervention: Cyanocobalamin (6 µg) vs 9 µg (normal status)
Number of subjects: 101
Study 29038891 — intervention group
Group type: COMPARATOR
Intervention: Cyanocobalamin vs Hydroxocobalamin
Number of subjects: 101
Study 29040030 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) plus Ipilimumab (IPI)
Number of subjects: 94
Study 29040162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 619
Study 29040433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low end-tidal CO2 (etCO2)
Number of subjects: 86
Study 29040433 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine administration
Number of subjects: 86
Study 29040433 — intervention group
Group type: EXPERIMENTAL
Intervention: etCO2 < 2.6 kPa (20 mm Hg)
Number of subjects: 86
Study 29040633 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-naive adults
Number of subjects: 987
Study 29040633 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-experienced adults
Number of subjects: 987
Study 29040633 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-naive children
Number of subjects: 987
Study 29040633 — intervention group
Group type: EXPERIMENTAL
Intervention: ARV-naive women aged 18-24 years
Number of subjects: 987
Study 29040633 — intervention group
Group type: EXPERIMENTAL
Intervention: Age in females
Number of subjects: 987
Study 29040638 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone < 9.2 ng/ml
Number of subjects: 244
Study 29040638 — intervention group
Group type: COMPARATOR
Intervention: Serum progesterone ≥ 9.2 ng/ml
Number of subjects: 244
Study 29040638 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone quartiles Q1-Q4
Number of subjects: 244
Study 29040638 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for serum P < 9.2 ng/ml
Number of subjects: 244
Study 29040638 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum progesterone predictive value
Number of subjects: 244
Study 29041923 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 980
Study 29041979 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 113
Study 29041979 — intervention group
Group type: COMPARATOR
Intervention: Anti-tumor necrosis factor (anti-TNF) treatment with or without MTX
Number of subjects: 113
Study 29041979 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX group
Number of subjects: 113
Study 29041979 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF ± MTX group
Number of subjects: 113
Study 29042362 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 0
Study 29042362 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 29042364 — intervention group
Group type: EXPERIMENTAL
Intervention: CD200R-CD28 fusion protein
Number of subjects: 0
Study 29042364 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy with genetically modified T cells
Number of subjects: 0
Study 29042367 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 302
Study 29042391 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass
Number of subjects: 100
Study 29042397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low osmolality contrast (n=574)
Number of subjects: 763
Study 29042397 — intervention group
Group type: COMPARATOR
Intervention: Iso-osmolality contrast (n=189)
Number of subjects: 763
Study 29042397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast volume (n=341)
Number of subjects: 763
Study 29042397 — intervention group
Group type: COMPARATOR
Intervention: High contrast volume (n=422)
Number of subjects: 763
Study 29042398 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral TAVR with PAD
Number of subjects: 19660
Study 29042398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontransfemoral TAVR with PAD
Number of subjects: 19660
Study 29042398 — intervention group
Group type: COMPARATOR
Intervention: Control group (without PAD)
Number of subjects: 19660
Study 29042492 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Interview of Cognitive Status (TICS)
Number of subjects: 105
Study 29042492 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Montreal Cognitive Assessment (T-MoCA)
Number of subjects: 105
Study 29042492 — intervention group
Group type: COMPARATOR
Intervention: Clinical Dementia Rating
Number of subjects: 105
Study 29043014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab (300 mg subcutaneously) administered every 2 weeks after an initial dose on Day 0 and after the first confirmed angioedema attack for rollover patients.
Number of subjects: 0
Study 29043014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab (300 mg subcutaneously) administered every 2 weeks for non-rollover patients regardless of the first attack.
Number of subjects: 0
Study 29043263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 0
Study 29043263 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 0
Study 29043263 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29043407 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid surgery
Number of subjects: 33
Study 29044787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation using a 6-mm distal electrode catheter
Number of subjects: 397
Study 29045037 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ficolin-2 antibodies in SLE patients
Number of subjects: 165
Study 29045037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-ficolin-2, anti-ficolin-3, and anti-C1q
Number of subjects: 165
Study 29045487 — intervention group
Group type: EXPERIMENTAL
Intervention: Active SCD-associated leg ulcers
Number of subjects: 20
Study 29045540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg i.v. Q3weeks until disease progression
Number of subjects: 12
Study 29045543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and trastuzumab (and hormonal therapy if HR-positive) for 18 weeks
Number of subjects: 151
Study 29045543 — intervention group
Group type: EXPERIMENTAL
Intervention: CelTIL score at D15
Number of subjects: 151
Study 29045543 — intervention group
Group type: EXPERIMENTAL
Intervention: CelTIL at D15 as a continuous variable
Number of subjects: 151
Study 29045543 — intervention group
Group type: EXPERIMENTAL
Intervention: CelTIL at D15 in LPT109096 trial
Number of subjects: 151
Study 29045736 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-B-cell activating factor antibody
Number of subjects: 2262
Study 29045736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2262
Study 29045739 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg bodyweight ketamine administered once i.v.
Number of subjects: 12
Study 29046319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Fentanyl
Number of subjects: 0
Study 29046319 — intervention group
Group type: COMPARATOR
Intervention: Control (no Fentanyl)
Number of subjects: 0
Study 29046921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 14
Study 29046921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 14
Study 29047049 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic Swallowing Study (FSS)
Number of subjects: 9386
Study 29047049 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 9386
Study 29047049 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FSS and CT
Number of subjects: 9386
Study 29047161 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic donor lymphocyte infusion (DLI)
Number of subjects: 35
Study 29047161 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) GVHD prophylaxis
Number of subjects: 35
Study 29047411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate level > 1.5 mmol/L
Number of subjects: 257
Study 29047411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly elevated lactate levels (1-2 mmol/L)
Number of subjects: 257
Study 29048177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care intervention (in-person consultation, weekly nurse coach-facilitated phone sessions, monthly follow-up)
Number of subjects: 529
Study 29048177 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 529
Study 29048177 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (12 weeks after enrollment)
Number of subjects: 529
Study 29049219 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA)
Number of subjects: 790
Study 29049219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspinal anesthesia including epidural anesthesia (EA)
Number of subjects: 790
Study 29049219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 790
Study 29049219 — intervention group
Group type: COMPARATOR
Intervention: Morbid obesity
Number of subjects: 790
Study 29049798 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging with indocyanine green (ICG)
Number of subjects: 4
Study 29049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by Misoprostol (800 μg buccal) after 24 hours
Number of subjects: 1744
Study 29049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in primary facilities
Number of subjects: 1744
Study 29049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in secondary facilities
Number of subjects: 1744
Study 29049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone and Misoprostol in specialty hospital
Number of subjects: 1744
Study 29050505 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom checklists for ADHD
Number of subjects: 239
Study 29050505 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic procedures (parent, teacher, and self-reports)
Number of subjects: 239
Study 29050505 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of substance use context
Number of subjects: 239
Study 29050505 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive psychiatric assessments
Number of subjects: 239
Study 29050505 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of impairment and psychiatric history
Number of subjects: 239
Study 29050557 — intervention group
Group type: EXPERIMENTAL
Intervention: instantaneous wave-free ratio (iFR)
Number of subjects: 763
Study 29050557 — intervention group
Group type: EXPERIMENTAL
Intervention: resting distal to aortic coronary pressure (P)
Number of subjects: 763
Study 29050558 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting distal to aortic coronary pressure (Pd/Pa)
Number of subjects: 435
Study 29050558 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous wave-free ratio (iFR)
Number of subjects: 435
Study 29050636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to enhance self-regulation skills (executive functioning, emotion regulation, future-oriented thinking, approach bias) delivered via home visits.
Number of subjects: 0
Study 29050636 — intervention group
Group type: EXPERIMENTAL
Intervention: Assays of self-regulation and obesogenic eating behaviors using behavioral tasks and self-reports.
Number of subjects: 0
Study 29051021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg dose identified as maximum tolerated dose)
Number of subjects: 33
Study 29051021 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg dose)
Number of subjects: 33
Study 29051021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment anti-PDGFRA antibody levels ≥ .150 optical density
Number of subjects: 33
Study 29051134 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based telerehabilitation intervention (8 weekly, 1-hour sessions)
Number of subjects: 24
Study 29051134 — intervention group
Group type: COMPARATOR
Intervention: Regular routine (control group)
Number of subjects: 24
Study 29051281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fanconi anemia and dyskeratosis congenita
Number of subjects: 0
Study 29051281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia
Number of subjects: 0
Study 29051281 — intervention group
Group type: EXPERIMENTAL
Intervention: Shwachman-Diamond syndrome
Number of subjects: 0
Study 29051281 — intervention group
Group type: COMPARATOR
Intervention: Stem cell transplantation in Fanconi anemia and dyskeratosis congenita
Number of subjects: 0
Study 29051281 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 29051829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 616
Study 29052073 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic primary cytoreduction (LPC)
Number of subjects: 66
Study 29052073 — intervention group
Group type: COMPARATOR
Intervention: Abdominal primary cytoreduction (APC)
Number of subjects: 66
Study 29052519 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (24-week course, starting 3 months post-TKA)
Number of subjects: 34
Study 29052519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no circuit training)
Number of subjects: 34
Study 29052782 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD4 TCR-transduced T cells
Number of subjects: 3
Study 29053802 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800 mg, algal oil) daily from 26 weeks to term
Number of subjects: 38
Study 29053802 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn/soy oil) daily from 26 weeks to term
Number of subjects: 38
Study 29054476 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicles (EVs)
Number of subjects: 0
Study 29054476 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor cell-derived EVs
Number of subjects: 0
Study 29054476 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal-derived EVs
Number of subjects: 0
Study 29054589 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 806
Study 29054734 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-facilitated screening and brief advice (cSBA)
Number of subjects: 2685
Study 29054734 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 2685
Study 29054833 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based screening intervention group (n=305)
Number of subjects: 636
Study 29054833 — intervention group
Group type: COMPARATOR
Intervention: Paper-based screening control group (n=331)
Number of subjects: 636
Study 29054833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (e-screening and paper-based)
Number of subjects: 636
Study 29054923 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 19
Study 29055438 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide for 48 weeks
Number of subjects: 1000
Study 29055438 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide for 48 weeks (switchers)
Number of subjects: 1000
Study 29055637 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Mellitus (DM)
Number of subjects: 547
Study 29055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Diabetes (pre-DM)
Number of subjects: 547
Study 29055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glucose Metabolism (NGM)
Number of subjects: 547
Study 29055736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT lung cancer screening
Number of subjects: 2537
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECG characteristics
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HR <30 bpm
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial HR <30 bpm and QRS≥120 ms
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Location of arrest
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine use
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: ALS paramedic on scene
Number of subjects: 332
Study 29055890 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful intubation
Number of subjects: 332
Study 29056470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, Cladribine, and Rituximab (VCR)
Number of subjects: 24
Study 29056570 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3759 at 200 mg twice a day
Number of subjects: 67
Study 29056570 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD3759 at 300 mg twice a day
Number of subjects: 67
Study 29056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based chILD management platform with a registry and biobank
Number of subjects: 575
Study 29056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary review by expert clinicians
Number of subjects: 575
Study 29056600 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcategorisation into chILD-EU register classification
Number of subjects: 575
Study 29057117 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC)
Number of subjects: 0
Study 29057117 — intervention group
Group type: COMPARATOR
Intervention: Dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC)
Number of subjects: 0
Study 29057120 — intervention group
Group type: EXPERIMENTAL
Intervention: US-IVC guided fluid management (Group 1)
Number of subjects: 33